3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Unknown
2
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
6
Esophageal Squamous Cell Carcinoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Medulloblastoma
1
Locally Advanced Rectal Carcinoma
1
High-Risk Cancer
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Breast Cancer Metastatic
1
Breast Cancer Invasive
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Paclitaxel
17
Carboplatin
16
Magnetic Resonance Spectroscopy
11
Taxes
10
Specimen Handling
10
Bevacizumab
10
olaparib
9
Gemcitabine
9
pembrolizumab
8
Immunoglobulin G
7
Disulfides
7
Biopsy
7
liposomal doxorubicin
6
Doxorubicin
5
cediranib
4
Nivolumab
4
Cyclophosphamide
4
Cisplatin
4
oregovomab
3
niraparib
3
adavosertib
3
X-Rays
3
Topotecan
3
tremelimumab
2
rucaparib
2
mirvetuximab soravtansine
2
berzosertib
2
aldesleukin
2
Surveys and Questionnaires
2
Platinum
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Fallopian Tube Neoplasms
×
Neoadjuvant Therapy
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled